We are live on
!
Find out more
Balyasny Asset Management Portfolio holdings
AUM
$77.1B
1-Year Est. Return
42.89%
This Fund
S&P 500
This Quarter
Est. Return
+1.22%
1 Year Est. Return
+42.89%
3 Year Est. Return
+126.29%
5 Year Est. Return
+172.74%
10 Year Est. Return
+1,026.86%
AUM
$57.1B
AUM Growth
-$109M
(-0.19%)
Cap. Flow
-$507M
Cap. Flow
% of AUM
-0.89%
Top 10 Holdings %
Top 10 Hldgs %
13.27%
Holding
3,274
New
730
Increased
855
Reduced
816
Closed
774
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$444M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$430M |
| 3 |
Wells Fargo
WFC
|
+$281M |
| 4 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$263M |
| 5 |
ConocoPhillips
COP
|
+$234M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$777M |
| 2 |
Meta Platforms (Facebook)
META
|
+$317M |
| 3 |
TSMC
TSM
|
+$308M |
| 4 |
JPMorgan Chase
JPM
|
+$246M |
| 5 |
ASML
ASML
|
+$231M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 9.54% |
| 2 | Consumer Discretionary | 9.3% |
| 3 | Financials | 8.79% |
| 4 | Technology | 8.62% |
| 5 | Healthcare | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TSBX
2351
DELISTED
Turnstone Biologics
TSBX
| $141K | ﹤0.01% |
53,682
+20,936
| +64% | +$59.8K |
|
2352
Baytex Energy
BTE
$3.08B
| $140K | ﹤0.01% |
40,237
-10,654
| -21% | -$38.1K |
|
2353
Ranpak Holdings
PACK
$461M
| $135K | ﹤0.01% |
+20,929
| New | +$141K |
|
2354
Orthofix Medical
OFIX
$420M
| $133K | ﹤0.01% |
+10,061
| New | +$138K |
|
2355
Akebia Therapeutics
AKBA
$240M
| $132K | ﹤0.01% |
129,896
-48,897
| -27% | -$60.4K |
|
|
PARA
2356
CALL
DELISTED
Paramount Global Class B
PARA
| $132K | ﹤0.01% |
+12,700
| New | +$149K |
|
2357
EverCommerce
EVCM
$1.75B
| $132K | ﹤0.01% |
+11,982
| New | +$116K |
|
2358
CALL
Opendoor
OPEN
$3.48B
| $132K | ﹤0.01% |
+73,883
| New | +$159K |
|
|
TERN
2359
DELISTED
Terns Pharmaceuticals
TERN
| $130K | ﹤0.01% |
+19,161
| New | +$116K |
|
|
DFTX
2360
Definium Therapeutics
DFTX
$5.43B
| $127K | ﹤0.01% |
+17,663
| New | +$154K |
|
2361
Cosan
CSAN
$2.54B
| $125K | ﹤0.01% |
+12,858
| New | +$139K |
|
2362
Allogene Therapeutics
ALLO
$732M
| $125K | ﹤0.01% |
53,622
+32,305
| +152% | +$95.3K |
|
2363
Liquidia Corp
LQDA
$7.83B
| $123K | ﹤0.01% |
+10,250
| New | +$136K |
|
2364
Cognyte Software
CGNT
$692M
| $123K | ﹤0.01% |
+16,043
| New | +$120K |
|
2365
AngioDynamics
ANGO
$651M
| $118K | ﹤0.01% |
19,545
-5,542
| -22% | -$34.2K |
|
2366
Safe Bulkers
SB
$746M
| $113K | ﹤0.01% |
+19,438
| New | +$105K |
|
|
CEPU
2367
Central Puerto
CEPU
$2B
| $113K | ﹤0.01% |
+12,454
| New | +$122K |
|
2368
Savara
SVRA
$1.14B
| $112K | ﹤0.01% |
+27,833
| New | +$124K |
|
2369
3D Systems Corp
DDD
$633M
| $108K | ﹤0.01% |
+35,037
| New | +$128K |
|
2370
Patterson-UTI
PTEN
$4.22B
| $106K | ﹤0.01% |
10,253
-2,806,077
| -100% | -$30.8M |
|
2371
Adaptive Biotechnologies
ADPT
$4.04B
| $106K | ﹤0.01% |
29,227
+9,341
| +47% | +$29.6K |
|
|
DRD
2372
DRDGold
DRD
$2.07B
| $104K | ﹤0.01% |
+12,132
| New | +$103K |
|
2373
AbCellera Biologics
ABCL
$2.99B
| $103K | ﹤0.01% |
34,794
-23,716
| -41% | -$89.7K |
|
2374
Anavex Life Sciences
AVXL
$325M
| $103K | ﹤0.01% |
24,349
-58,731
| -71% | -$238K |
|
2375
Teladoc Health
TDOC
$1.24B
| $101K | ﹤0.01% |
10,311
-831,619
| -99% | -$10.1M |
|
Similar funds
CBU
BC
Balyasny Asset Management's Q2 2024 Portfolio in Review
As of Q2 2024, Balyasny Asset Management held 3,274 positions worth $57.1B, down 0.19% from $57.2B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Balyasny Asset Management's Q2 2024 filing shows 730 new, 855 increased, 816 reduced and 774 closed positions. Its largest new stake was Intercontinental Exchange: 1,498,857 shares worth $205M. The largest sale was Pioneer Natural Resource Co., an estimated $777M.
By sector, the portfolio is most concentrated in Industrials at 9.5% of assets, up from 8.1% a quarter earlier, followed by Consumer Discretionary and Financials.
- Balyasny Asset Management's largest Q2 2024 buy was Intercontinental Exchange: 1,498,857 shares worth $205M.
- Balyasny Asset Management added most to Apple in Q2 2024, an estimated $444M increase.
- Balyasny Asset Management's biggest Q2 2024 reduction was Meta Platforms (Facebook), cutting an estimated $317M.
- Balyasny Asset Management fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $777M.
- Balyasny Asset Management's ten largest holdings make up 13% of its $57.1B portfolio in Q2 2024.
- Balyasny Asset Management opened 730 new positions and closed 774 in Q2 2024.
- Balyasny Asset Management's portfolio value fell 0.19% quarter-over-quarter to $57.1B.
Based on Balyasny Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.